 Amgen Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompa
Table of contents List of tables / figures |
2008 |
5.700,00$ |
AstraZeneca plc: PharmaVitae Profile
This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile e
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Bayer Schering Pharma AG: PharmaVitae Profile
This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Bristol-Myers Squibb Co.: PharmaVitae Profile
This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompass
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
Analysis of clinical trial design and treatment guidelines in fibromyalgia. / / Fibromyalgia market sizing assessment with detail
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
Assessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compounds / / R
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth
Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017
/
/ Ana
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017
Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017
/
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare (analysis of monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial public offeri
Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis
Table of contents List of tables / figures |
2008 |
495,00$ |
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
Review of key reasons why lifecycle management is important now / / Analysis of key considerations Pharma need to take care of wh
Table of contents List of tables / figures |
2008 |
7.600,00$ |
